Vaccination Strategies against Highly Pathogenic Arenaviruses: The Next Steps toward Clinical Trials.
Fiche du document
2013
- doi: 10.1371/journal.ppat.1003212
- issn: 1553-7366
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1371/journal.ppat.1003212
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/23592977
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1553-7374
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_6347895092A89
info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer
Sujets proches
Arenaviridae ArenovirusesCiter ce document
S. Olschläger et al., « Vaccination Strategies against Highly Pathogenic Arenaviruses: The Next Steps toward Clinical Trials. », Serveur académique Lausannois, ID : 10.1371/journal.ppat.1003212
Métriques
Partage / Export
Résumé
Vaccination is one of the most valuable weapons against infectious diseases and has led to a significant reduction in mortality and morbidity. However, for most viral hemorrhagic fevers caused by arenaviruses, no prophylactic vaccine is available. This is particularly problematic as these diseases are notoriously difficult to diagnose and treat. Lassa fever is globally the most important of the fevers caused by arenaviruses, potentially affecting millions of people living in endemic areas, particularly in Nigeria. Annually, an estimated 300,000 humans are infected and several thousands succumb to the disease. The successful development of the vaccine "Candid#1" against Junin virus, the causative agent of Argentine hemorrhagic fever, proved that an effective arenavirus vaccine can be developed. Although several promising studies toward the development of a Lassa fever vaccine have been published, no vaccine candidate has been tested in human volunteers or patients. This review summarizes the immunology and other aspects of existing experimental arenavirus vaccine studies, discusses the reasons for the lack of a vaccine, and proposes a plan for overcoming the final hurdles toward clinical trials.